Merck + Co., Inc.

Jess Sager

Ralph P Volante

Kai Rossen

David Askin

Paul J Reider

Philip J Pye

Ashok Maliakal

Robert D Larsen

Ian W Davies

Steven A Weissman

Edward G Corley

Daniel Richard Sidler

Jean-Francois Marcoux

The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.

Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2

The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1##

An improved process using chiral hydrogenation is described for the synthesis in high yields of a 4-protected-(S)-piperazine-2-tert-butyl-carboxamide, an intermediate for an HIV protease inhibitor.

Process for preparing

A process for making a clinically efficacious HIV protease inhibitor Compound J eliminates one step in its synthesis, by an improved, alternative synthesis of the 2(S)-4-picolyl-2-piperazine-t-butyl-carboxamide intermediate.

Process for making HIV protease inhibitors

Growing community of inventors

Bridgewater, NJ, United States of America

Jess Sager